Bausch Health's CEO Takes Over Bausch + Lomb As Ousted CEO Gets About $75 Million

Brent Saunders left Bausch + Lomb on October 12 with a lump-sum payment, and Bausch Health CEO Thomas Appio is now interim chief.

Share
Bausch Health's CEO Takes Over Bausch + Lomb As Ousted CEO Gets About $75 Million

Bausch + Lomb CEO Brent Saunders left the company on October 12 with a lump-sum cash payment of about $75 million, and Bausch Health CEO Thomas Appio stepped in as B+L's interim chief, according to Bausch Health's 10-Q filed Thursday. Bausch Health, a specialty drug and medical device maker that owns about 87% of the eye-health company, also disclosed a $50 million buyback and a $643 million note redemption.

A separation agreement and a dual role

Saunders departed as B+L's chief executive and as a director under a separation agreement entered into on October 11. The filing says he left under a mutual agreement with the B+L board, and all of his outstanding B+L equity awards were forfeited and cancelled.

Appio keeps his Bausch Health job while running B+L on an interim basis. The filing's forward-looking statements flag the recent changes to the B+L board and leadership, including Appio's appointment as chairman and interim CEO while he concurrently serves as Bausch Health's CEO.

The exit comes in a quarter when B+L's segment profit rose to $410 million from $301 million a year earlier, on revenue of $1,375 million, up 7%.

A buyback and a debt paydown

Bausch Health's board authorized a share repurchase of up to $50 million on October 24. The earnings release said the primary aim is offsetting dilution from management equity awards expected to vest in 2027. The program does not obligate the company to buy any set amount.

On October 28 the company said subsidiary Bausch Health Americas will issue an irrevocable notice to redeem all of its 8.500% senior notes due 2027, about $643 million in principal. The redemption is set for November 30 and will be paid from cash on hand. The company held $2,485 million in cash at September 30.

Quarter results and the Salix goodwill

Third-quarter revenue rose 10% to $2,941 million, and net income attributable to Bausch Health was $436 million, against $179 million a year earlier. For the first nine months the company reported a net loss of $729 million, driven by a $1,426 million goodwill impairment at its Salix unit after two late-stage trials failed their main goals.

Salix, which sells U.S. gastrointestinal products, about 85% of them Xifaxan, still carries $1,733 million of goodwill. The filing warns that worsening conditions or missed strategy could force further impairment charges that could be material.

Separately, B+L received an FDA warning letter in September after an Official Action Indicated finding at its Tampa, Florida plant. The company says the letter requires no shutdown or recall, and the plant continues to ship products.

The $643 million redemption is scheduled for November 30.

Sources

More on Bausch Health

All Bausch Health (BHC) coverage →